Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

@article{Rothwell2011EffectOD,
  title={Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials},
  author={P. Rothwell and F. G. Fowkes and J. F. Belch and H. Ogawa and T. Meade},
  journal={The Lancet},
  year={2011},
  volume={377},
  pages={31-41}
}
  • P. Rothwell, F. G. Fowkes, +2 authors T. Meade
  • Published 2011
  • Medicine
  • The Lancet
  • BACKGROUND Treatment with daily aspirin for 5 years or longer reduces subsequent risk of colorectal cancer. Several lines of evidence suggest that aspirin might also reduce risk of other cancers, particularly of the gastrointestinal tract, but proof in man is lacking. We studied deaths due to cancer during and after randomised trials of daily aspirin versus control done originally for prevention of vascular events. METHODS We used individual patient data from all randomised trials of daily… CONTINUE READING
    1,184 Citations

    Paper Mentions

    Interventional Clinical Trial
    The purpose of the study is to observe the effect of sorafenib combined with aspirin in preventing the recurrence in high-risk patients with hepatocellular carcinoma.  
    ConditionsHepatocellular Carcinoma
    InterventionDrug, Other
    Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
    • 13
    • PDF
    Will an aspirin a day help keep fatal cancer away?
    • 8
    Daily aspirin use and cancer mortality in a large US cohort.
    • 68
    • PDF

    References

    SHOWING 1-10 OF 60 REFERENCES
    Aspirin for the primary prevention of vascular events?
    • 18
    Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
    • 393
    • PDF